











WHAT IS CLAIMED IS:

1. A method for the treatment of cancerous cell growth mediated by raf kinase, comprising administering a compound of the formulae:


5




10









5





10






5







or




10




2. A method according to claim 1, comprising administering a compound of the formulae















or



3. A method according to claim 1, comprising administering a compound of the formulae







5

10


T00070"00055460




or




4. A method according to claim 1, comprising administering a compound of formulae




or







5. A method according to claim 1, comprising administering a compound of formulae




or













6. A method according to claim 1, comprising administering a compound of formulae



or



















7. A method according to claim 1, comprising administering a compound of formulae















10

BrCC1=C(C(=O)OC)SC=C1








5




10





5






9. A compound according to claim 8, of the formulae







10

10. A compound according to claim 8, of the formulae


5




10











12. A compound according to claim 8, of the formulae




or




13. A compound according to claim 8, of the formulae











or






14. A compound according to claim 8, of the formulae







- 5
- 10      15.    A pharmaceutical composition comprising a compound according to claim 8 and a physiologically acceptable carrier.
- 15      16.    A pharmaceutical composition comprising a compound according to claim 14 and a physiologically acceptable carrier.
17.    A pharmaceutical composition comprising a compound according to claim 8 and a physiologically acceptable carrier, in sterile form.

Handwritten signature and initials.